A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Part of paid clinical trials in Port Orange, Florida.

Sponsor
CRISPR Therapeutics AG
Study ID
NCT07758634
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CTX340 — DRUG
    CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.
  • Placebo — DRUG
    One of the arms in Phase 2 will be placebo.

Study Details

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Key Dates

First listed
Aug 11, 2026
Start date
Aug 8, 2026
Status verified
Aug 2026
Primary completion
Jul 1, 2028
Completion
Jul 1, 2029

Study Design

Enrollment
69 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1: CTX340
    Phase 1 is An Open-Label, Ascending Dose Design.
  • Experimental: Phase 2: Recommended Phase 2 Dose CTX340
    Phase 2: Recommended Phase 2 Dose CTX340.
  • Experimental: Phase 2: Placebo
    Phase 2: Placebo.

Primary Outcome Measure

Phase 1: Incidence of dose-limiting toxicities (DLTs) [ Time Frame: Up to 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research Site 1Port OrangeFlorida32127-

Find similar trials in Port Orange, FL

Nationwide
Hypertension (high blood pressure) trialsCardiology trialsHeart disease trials
By condition
Hypertension (high blood pressure)
By specialty
CardiologyHeart disease
By research site
Research· Port Orange, FL

Related Studies